ALK-Abelló Must Report Managerial Staff Transactions Under EU Market Abuse Regulation
1 report, 1 independent
Updated Sun 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ALK-Abelló A/S is required to report transactions made by its managerial staff. This requirement is mandated by Article 19 of Regulation (EU) No 596/2014 on market abuse.
From manilatimes.net
Why it matters
The regulatory action imposes a formal reporting obligation on ALK-Abelló. This requirement relates to compliance with European market abuse regulations.
From manilatimes.net
Who's involved
- ALK-AbellóDanish pharmaceutical company subject to the reporting requirement
- Edward JordanHolds the executive vice president role for ALK North America
- Health CanadaGrants regulatory approval to ALK-Abelló for market access
- National Health ServiceProcures and makes available products supplied by ALK-Abelló
- National Institute for Health and Care ExcellenceFormally recommended ALK-Abelló's allergy tablets, influencing UK market access
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- ALK-AbellóSpeculative
ALK-Abelló might face increased compliance costs related to reporting managerial staff transactions.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
ALK-Abelló
Danish pharmaceutical company
Nothing else this week.